MAIA Biotechnology (MAIA) announced the publication of preclinical data for its lead proprietary telomere-targeting THIO dimer in the ...

“Our manuscript highlights the potential of THIO’s dimer as a potent GSTP1 inhibitor and a promising new strategy for enhancing cancer treatment and overcoming drug resistance,” said Chief ...

In a preclinical study, THIO and its new described dimer form were found to be potent ... by effectively targeting GSTP1 and reducing drug resistance. The article, titled “Investigation of ...

Although D-dimer results within a typical range can rule out pulmonary embolism, high results alone can’t diagnose this condition. Doctors usually need to run extra tests to make a diagnosis.

This dimer can exist in two conformations ... The whole P-cadherin/antibody/drug complex is then sent to a structure called the lysosome to be broken down. "Our results establish an outside ...

The study aims to address the uncertainty surrounding the safety of excluding PE based on D-dimer levels in high-risk patients. Lead author Héloïse Bannelier, MD, and colleagues conducted a post ...